Farglitazar

Farglitazar
Systematic (IUPAC) name

N-(o-benzoylphenyl)-O-[2-(5-methyl- 2-phenyl-4-oxazolyl)ethyl]-L-tyrosine
Clinical data
Pregnancy category	N/A
Legal status	Investigational
Identifiers
CAS Registry Number	196808-45-4^N
ATC code	None
PubChem	CID 170364
IUPHAR ligand	2672
ChemSpider	148961^N
UNII	3433GY7132^Y
ChEMBL	CHEMBL107367^N
Chemical data
Formula	C₃₄H₃₀N₂O₅
Molecular mass	546.612 g/mol
SMILES O=C(c1ccccc1)c2ccccc2N[C@H](C(=O)O)Cc5ccc(OCCc3nc(oc3C)c4ccccc4)cc5
InChI InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 ^N Key:ZZCHHVUQYRMYLW-HKBQPEDESA-N ^N
N (what is this?) (verify)

Farglitazar is a peroxisome proliferator-activated receptor agonist which is being developed by GlaxoSmithKline for the treatment of hepatic fibrosis. It is currently in phase II clinical trials.

References